Present address: Brazos Valley Equine Hospital, Navasota, TX 77868, USA.
Pharmacokinetics of ceftiofur sodium and ceftiofur crystalline free acid in neonatal foals
Article first published online: 18 NOV 2010
© 2010 Blackwell Publishing Ltd
Journal of Veterinary Pharmacology and Therapeutics
Volume 34, Issue 4, pages 403–409, August 2011
How to Cite
HALL, T. L., TELL, L. A., WETZLICH, S. E., McCORMICK, J. D., FOWLER, L. W. and PUSTERLA, N. (2011), Pharmacokinetics of ceftiofur sodium and ceftiofur crystalline free acid in neonatal foals. Journal of Veterinary Pharmacology and Therapeutics, 34: 403–409. doi: 10.1111/j.1365-2885.2010.01252.x
- Issue published online: 6 JUL 2011
- Article first published online: 18 NOV 2010
- (Paper received 3 May 2010; accepted for publication 6 October 2010)
Hall, T. L., Tell, L. A., Wetzlich, S. E., McCormick, J. D., Fowler, L. W., Pusterla, N. Pharmacokinetics of ceftiofur sodium and ceftiofur crystalline free acid in neonatal foals. J. vet. Pharmacol. Therap.34, 403–409.
Ceftiofur, a third generation cephalosporin, demonstrates in vitro efficacy against microorganisms isolated from septicemic neonatal foals. This pharmacokinetic study evaluated the intravenous and subcutaneous administration of ceftiofur sodium (5 mg/kg body weight; n = 6 per group) and subcutaneous administration of ceftiofur crystalline free acid (6.6 mg/kg body weight; n = 6) in healthy foals. Plasma ceftiofur- and desfuroylceftiofur-related metabolite concentrations were measured using high performance liquid chromatography following drug administration. Mean (±SD) noncompartmental pharmacokinetic parameters for i.v. and s.c. ceftiofur sodium were: AUC0∝ (86.4 ± 8.5 and 91 ± 22 h·μg/mL for i.v. and s.c., respectively), terminal elimination half-life (5.82 ± 1.00 and 5.55 ± 0.81 h for i.v. and s.c., respectively), Cmax(obs) (13 ± 1.9 μg/mL s.c.), Tmax(obs) (0.75 ± 0.4 h for s.c.). Mean (± SD) noncompartmental pharmacokinetic parameters for s.c. ceftiofur crystalline free acid were: AUC0∝ (139.53 ± 22.63 h·μg/mL), terminal elimination half-life (39.7 ± 14.7), Cmax(obs) (2.52 ± 0.35 μg/mL) and tmax(obs) (11.33 ± 1.63 h). No adverse effects attributed to drug administration were observed in any foal. Ceftiofur- and desfuroylceftiofur-related metabolites reached sufficient plasma concentrations to effectively treat common bacterial pathogens isolated from septicemic foals.